Summary
No FDA-approved prescribing information text was provided (only Indications and Usage section label index). Therefore none of the extracted labeling/branding claims can be verified against the supplied label content.
Category Scores
Accurate Statements
Unsupported Statements
Perampanel is the generic name (INN) of the drug.
Not supported or verifiable because no relevant FDA label text (e.g., Drug Name/Description) was provided.
Perampanel is sold under brand names such as Fycompa in some markets.
Not supported or verifiable because no relevant FDA label text listing brand/trade names was provided.
The active ingredient’s generic name remains "perampanel".
Not supported or verifiable because no FDA label text identifying active ingredient/generic naming was provided.
Brand name differs by country while the generic name stays the same.
Not supported or verifiable because no FDA label text addressing country-specific branding was provided.
Contradictions
Important Omissions
FDA label excerpts (verbatim) that identify the generic name and any approved trade/brand names (commonly in Description/Drug Name sections) are missing; only Indications and Usage section header was indicated with no text.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims are about naming/branding rather than dosing, contraindications, or safety. However, the inability to verify against the supplied FDA label content prevents confirming labeling accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Cannot verify any extracted naming/branding claims because no FDA label text was provided for the relevant sections.
Suggested Improvement
Provide the exact FDA label excerpts (or section text) that state the drug name/generic name and any approved trade name(s) so each claim can be checked for support.